MicuRx Pharmaceuticals, a Chinese clinical-stage antimicrobial drug developer, has secured a RMB300 million (US$43.11 million) series D round of financing led by HG Capital. Zero2IPO Asset Management and Sinopharm-CICC, a private equity fund focused on investments in the healthcare industry under CICC Capital, also participated in the round. Proceeds of the round will be mainly […] HG Capital Leads Series D Round In MicuRx Pharmaceuticals comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.